会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 6. 发明申请
    • Method of diagnosing integration dysfunction syndrome using blood
    • 使用血液诊断综合功能障碍综合征的方法
    • US20060099593A1
    • 2006-05-11
    • US10528433
    • 2003-09-26
    • Hiroyuki NawaToshiyuki SomeyaTatsuyuki MuratakeMeiko Kawamura
    • Hiroyuki NawaToshiyuki SomeyaTatsuyuki MuratakeMeiko Kawamura
    • C12Q1/68C12M1/34
    • C12Q1/6883C12Q2600/158G01N33/5091G01N33/6896G01N2800/302
    • An object of the present invention is. to provide an objective method for diagnosis of schizophrenia using gene expression in mononuclear cells of peripheral blood as an index, and this invention provide a method for diagnosing whether a test subject suffers from schizophrenia or not. The method according to this invention is a method for diagnosing whether a test subject suffers from schizophrenia or not, the method comprising the steps of; obtaining mononuclear cells in blood containing nucleic acid from said subject, measuring the content of at least one nucleic acid selected from the group consisting of nucleic acid(s) (containing its fragment and a nucleic acid complementary to the nucleic acid) defining gene(s) exhibiting altered expression by occurrence of schizophrenia or nucleic acid(s) (containing its fragment and a nucleic acid complementary to the nucleic acid) defining gene(s) exhibiting altered expression by progression of schizophrenia in said mononuclear cells, and determining alteration of the quantified level(s) of the gene(s) in said test subject is statistically significant in comparison with the quantified level(s) of said nucleic acid(s) defining gene(s) exhibiting altered expression by occurrence of schizophrenia or said nucleic acid(s) defining gene(s) exhibiting altered expression by progression of schizophrenia in healthy subjects or schizophrenic patients, thereby diagnosing whether said subject is suffering from schizophrenia or not.
    • 本发明的目的是。 以使用外周血单核细胞中的基因表达作为指标提供用于诊断精神分裂症的客观方法,本发明提供一种诊断受试者是否患有精神分裂症的方法。 根据本发明的方法是用于诊断测试对象是否患有精神分裂症的方法,所述方法包括以下步骤: 获得来自所述受试者的含有血液的核酸中的单核细胞,测量选自核酸(含有其与核酸互补的核苷酸)的至少一种核酸的含量,所述核酸定义基因 )通过发生精神分裂症或核酸(含有其与核酸互补的核酸)表现出改变的表达,所述基因通过所述单核细胞中精神分裂症的进展表现出改变的表达,并且确定 与所述定义的基因的定义水平相比,所述测试受试者中的基因的定量水平与通过发生精神分裂症或所述核酸显示改变的表达的基因的定量水平相比是统计学显着的 定义通过健康受试者或精神分裂症患者的精神分裂症进展表现出改变的基因,由此诊断所述受试者 是否患有精神分裂症?
    • 8. 发明授权
    • Neurotrophic factor secretion promoters
    • 神经营养因子分泌促进剂
    • US06433019B1
    • 2002-08-13
    • US09601186
    • 2000-07-28
    • Hiroyuki Nawa
    • Hiroyuki Nawa
    • A61K3141
    • A61K31/5377A61K31/00A61K31/15A61K31/16A61K31/198A61K31/21A61K31/34
    • The present invention relates to a neurotrophic factor secretagogue, in particular, to a BDNF (brain-derived neurotrophic factor) secretagogue, which comprises as an active ingredient an NO donor. The medicament of the present invention promotes the secretion of neurotrophic factors from mammalian central neural cells. Thus, the medicament of the present invention, i.e., NO donor, is possibly applicable to the treatment of diseases caused by neutrotrophic factors, for example, neurodegenerative diseases, and is expected to exhibit the efficacious effects thereon. Also, the present invention provides a novel medication for neurodegenerative diseases.
    • 本发明涉及神经营养因子促分泌素,特别涉及BDNF(脑源性神经营养因子)促分泌素,其包含作为活性成分的NO供体。 本发明的药物促进哺乳动物中枢神经细胞分泌神经营养因子。 因此,本发明的药物即NO供体可能适用于治疗由中性营养因子引起的疾病,例如神经变性疾病,并且预期其对其有显着的效果。 另外,本发明提供了用于神经变性疾病的新型药物。